Menu Search
Equities

Harmony Biosciences Holdings Inc

HRMY:NMQ

Harmony Biosciences Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)35.06
  • Today's Change0.99 / 2.91%
  • Shares traded61.99k
  • 1 Year change+20.77%
  • Beta0.7778
Data delayed at least 15 minutes, as of Nov 25 2024 17:01 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Harmony Biosciences Holdings Inc had net income fall -28.99% from 181.47m to 128.85m despite a 32.93% increase in revenues from 437.86m to 582.02m. An increase in the cost of goods sold as a percentage of sales from 19.07% to 20.83% was a component in the falling net income despite rising revenues.
Gross margin78.65%
Net profit margin17.98%
Operating margin25.71%
Return on assets14.38%
Return on equity22.75%
Return on investment17.12%
More ▼

Cash flow in USDView more

In 2023, Harmony Biosciences Holdings Inc increased its cash reserves by 27.56%, or 67.40m. The company earned 219.39m from its operations for a Cash Flow Margin of 37.69%. In addition the company used 46.44m on investing activities and also paid 105.55m in financing cash flows.
Cash flow per share2.53
Price/Cash flow per share13.23
Book value per share10.46
Tangible book value per share8.37
More ▼

Balance sheet in USDView more

Harmony Biosciences Holdings Inc has a Debt to Total Capital ratio of 23.45%, a lower figure than the previous year's 37.84%.
Current ratio3.24
Quick ratio3.20
Total debt/total equity0.3064
Total debt/total capital0.2345
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.